Eli Lilly & Co. is stepping up its fight against a booming black market for retatrutide, an experimental drug that the company is counting on to expand its crucial weight-loss franchise.
Eli Lilly has raised its 2026 revenue guidance to between $85 billion and $87 billion, up from a previous estimate of $82 billion to $85 billion. This adjustment follows a stronger-than-expected second-quarter performance driven by high demand for its weight-loss and diabetes drugs, particularly Mounjaro and Zepbound.
Eli Lilly has reported a strong quarter, leading to an increase in its price target. The strength of its GLP-1 business suggests the stock still has more room to run.
Eli Lilly & Co. boosted its 2026 sales guidance after its weight-loss drug franchise performed far better than expected in the second quarter, helping to counter investor concerns that the obesity drug boom is starting to slow.
Eli Lilly reported strong quarterly earnings, easily surpassing estimates, driven by surging sales of Zepbound and Mounjaro. The company now expects 2026 revenue to come in between $85 billion and $87 billion, up from previous guidance of $82 billion to $85 billion.
Novo Nordisk has raised its earnings forecast, but Wall Street remains skeptical about the company's ability to achieve sustainable growth. The skepticism is fueled by increasing competition from Eli Lilly in the obesity treatment market.
Eli Lilly is allowing more patients early access to its experimental weight loss drug retatrutide. Doctors are seeking ways to obtain the drug for their patients after one individual was granted early access.
Wall Street’s appetite for weight-loss drug stocks over the past four years has powered Eli Lilly & Co. to consistently trade above $1,000 per share. Now, some see the pharma giant’s stock as primed for a split.
Novo Nordisk and Eli Lilly, the firms behind Ozempic, Wegovy and Zepbound, faced selling pressure on Friday.
Novo Nordisk, the maker of Ozempic, is suing Eli Lilly over advertisements comparing some of their biggest-selling drugs. The ads compare Lilly’s Zepbound with Novo’s Wegovy, and Novo argues they give consumers a misleading picture of how the blockbuster weight-loss drugs stack up.
Eli Lilly’s triple-G drug retatrutide has hit the primary endpoints of a pair of phase 3 obesity trials, although the peak weight loss fell short of previous trials while failing to prove the drug reduces cardiovascular risk.
Eli Lilly & Co.’s highly anticipated next-generation weight-loss shot didn’t increase overall heart risk in a new study, the company said, helping dispel lingering concerns over its potential as it nears regulatory review.
Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'
Eli Lilly is suing pharmacies and peptide vendors over early sales of the next big weight-loss drug: retatrutide
Eli Lilly Sues Sellers of Black Market Weight-Loss Drugs
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide
Nvidia, Eli Lilly, and Disney Show It's Time to Back the Top Dogs
Broad Market Momentum & Defensive Pivots: This Week's Top ETF Flows
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy.
Nasdaq Falls Over 100 Points; Eli Lilly Shares Gain On Upbeat Earnings
Eli Lilly Stock Jumps on Earnings Beat Fueled by Weight-Loss Drugs
Eli Lilly Could Swing $65.9 Billion After Earnings
How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings
Eli Lilly to offer early access to next-gen obesity drug to some patients
Obesity battle heats up again as Novo claws way back into race with Lilly
Jobs Report, Palantir, AMD, SpaceX, Eli Lilly, and More to Watch This Week